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Abstract
 
All adult BALB/c mice immunized with hen egg white lysozyme (HEL) or its dominant deter-
minant, peptide (p)106–116, mount a T cell response using a “public” V
 
b
 
8.2J
 
b
 
1.5 T cell
clone. Neonatal exposure to tolerance-inducing doses of antigen can drastically diminish re-
sponsiveness in the draining lymph nodes but not in the spleens of animals challenged as adults
with the cognate antigen. To determine the role of T cell deletion or anergy within the mech-
anisms of observed neonatal “tolerance,” we treated neonatal BALB/c mice with HEL and di-
rectly followed the characteristic public clone using complementarity determining region 3
length T cell repertoire analysis. Our results confirm that despite intraperitoneal injection of
neonates with a high dose of HEL emulsified in incomplete Freund’s adjuvant, a strong splenic
proliferative response to HEL was observed upon recall. However, the adult splenic T cell re-
sponse of these neonatally treated mice lacked the usual V
 
b
 
8.2J
 
b
 
1.5 public clone characteristic
of HEL-primed BALB/c mice. After challenge with HEL–complete Freund’s adjuvant as
adults, immunoglobulin (Ig)G2a isotype antibody was drastically reduced, and IgG1 was found
to be the predominant anti-HEL IgG isotype expressed, indicating a deviation of cytokine re-
sponse toward T helper type 2. 5-wk-old mice, nasally instilled with tolerogenic doses of HEL
p106–116, also showed significant inhibition of this public T cell expansion. These results
demonstrate that during neonatal and adult nasal tolerance induction, deletion/anergy removes
the public clone, exposing a response of similar specificity but that is characterized by the T
helper type 2 phenotype and a splenic residence.
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Introduction
 
Early discussions of transplantation tolerance and high dose
tolerance (1, 2) revolved around the debate as to whether
they represented a “central” or a “peripheral” response def-
icit. Recently, this discussion has centered on assessing roles
of deletion or anergy versus cytokine deviation in Ag-
induced tolerance (3, 4). Additionally, regulation via Ag-
and receptor-centered devices has also been considered as a
plausible component of response tolerance (5–10).
Several experiments have supported the hypothesis that
tolerance to a minimal determinant results in clonal inacti-
vation via deletion or anergy (11), whereas direct thymic
studies demonstrate a loss of T cells by negative selection in
the thymus (12). Recently, however, additional studies
have suggested that Th1/Th2 deviation may be the sole
consequence of neonatal Ag administration (3, 4). In those
studies, neonatal BALB/c mice were given an intraperito-
neal injection of the model Ag, hen egg white lysozyme
(HEL)
 
1
 
 emulsified in IFA, and then were analyzed as adults
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for T cell–proliferative and cytokine recall responses to
cognate Ag. The results showed that although the draining
LN proliferative response was dramatically reduced, the
splenic proliferative response to Ag remained significant
and Th2 in nature (3, 4). A similar result was obtained in a
different H-2 haplotype using a high-level neonatal expo-
sure to a murine leukemia virus (13). These findings would
appear to contradict our previous results indicating that
neonatal tolerance to a minimal determinant results in
clonal inactivation via deletion or anergy (11). However,
the current results demonstrate that clonal inactivation of
Th1 cells can proceed concomitantly with the appearance
of different Th2 cells of the same antigenic specificity. In
this study, we have addressed the question of whether the
residual responsive splenic T cell repertoire seen in neona-
tally treated (“tolerized”) mice utilizes a qualitatively dif-
ferent responder T cell population compared with un-
treated mice. Splenic T cells were specifically targeted
because historically, LN cells display a classic “tolerant”
phenotype after neonatal treatment (11, 14, 15), whereas
splenic T cells remain responsive (3, 4).
In contrast to other studies that focus on the cytokine
profile of a single clone in response to in vitro stimulation
with altered peptide ligands (16) or differing Ag concentra-
tions (17, 18), we investigated the T cell repertoire after
tolerance induction at the clonal level within the poly-
clonal context of the spleen. This distinction allowed us to
directly follow the fate of the cell(s) as opposed to the fate
of the response.
Despite the existence of many other potential determi-
nants, BALB/c mice (H-2
 
d
 
) immunized with whole HEL
mount a response directed almost completely to a single
determinant of the molecule with a core of peptide
(p)108–116 (19). Most importantly, repertoire analysis has
identified a public TCR gene rearrangement that is used
by all BALB/c mice when mounting an anti-HEL T cell
response (20). This T cell expansion, originally described
by Cibotti et al. (20), has also held true for all unmanipu-
lated, HEL-primed BALB/c mice tested to date in our lab-
oratory. It is characterized by a TCR gene rearrangement
containing a V
 
b
 
8.2 variable region and a J
 
b
 
1.5 joining re-
gion that together encode for a CDR3 length of eight
amino acids, GTGNNQAP (20). The technique of CDR3
length repertoire analysis (immunoscope) allows such pub-
lic expansions to be followed in the presence of a poly-
clonal repertoire. Here we show that BALB/c mice toler-
ized as neonates with HEL in IFA can generate a
significant splenic proliferative response to HEL as adults;
however, this response excludes the public clone upon
subsequent challenge with HEL–CFA. Similar results were
obtained when animals were nasally instilled with p106–
116 and then challenged with HEL–CFA. Thus, these
methods of tolerance induction can induce both clonal de-
letion (or anergy) of the dominant T cell clone as well as
immune deviation of other Ag-specific T cells. These find-
ings demonstrate that previous observations concerning
clonal deletion and cytokine deviation of the T cell re-
 
sponse after neonatal exposure to Ag were describing the
fates of different populations.
 
Materials and Methods
 
Mice.
 
BALB/cJ mice were purchased from The Jackson Lab-
oratory and bred in our specific pathogen–free colony at the La
Jolla Institute for Allergy and Immunology. Neonatal mice used
in all experiments were age matched, housed in filter top cages,
and fed autoclaved chow. For the nasal instillation experiments,
the mice were also sex matched.
 
Neonatal Tolerance Induction.
 
Three groups of neonatal mice,
receiving a total of 0.01, 100, or 500 
 
m
 
g of HEL, were tolerized
as described (11). In brief, the two groups of neonates were given
intraperitoneal injections of 50 
 
m
 
l containing 0.005, 50, or 250
 
m
 
g of HEL, respectively. Injections were given within the first
18 h of life and then again at 72 h. HEL was dissolved in PBS and
emulsified 1:1 in IFA (Difco Labs., Inc.). A control group of neo-
nates was given intraperitoneal injections of IFA without Ag, also
administered at 18 and 72 h.
 
Adult Nasal Tolerance Induction.
 
Nasal instillation treatment
was initiated in female mice at 5 wk of age. Mice were separated
into two groups, one receiving 10 and the other 100 
 
m
 
g of HEL
p106–116 dissolved in 20 
 
m
 
l of PBS and delivered to the tip of
the nose after light anesthesia (halothane). 7 d later, animals were
given a second identical instillation. A control group was given
two 20-
 
m
 
l instillations of PBS, also 1 wk apart.
 
Adult Antigenic Challenge.
 
In neonatal tolerance experiments,
mice were immunized at 6 wk of age in the hind foot pads (
 
z
 
25
 
m
 
l per foot pad) with HEL emulsified 1:1 in CFA, such that each
mouse received a total of 100 
 
m
 
g of HEL–CFA. In the nasal in-
stillation experiments, mice were immunized with 100 
 
m
 
g of
HEL emulsified 1:1 in CFA 10 d after the final nasal instillation of
p106–116. 14 d after the HEL–CFA immunization, tissues were
harvested.
 
Tissue Culture.
 
Individual spleens and LNs were aseptically
removed, and single-cell suspensions were prepared in petri
dishes containing DME (GIBCO BRL Life Technologies, Inc.).
Large debris was removed by decanting, followed by two washes
in DME. Splenocytes and LN cells were adjusted to 6 
 
3
 
 10
 
6
 
 and
4 
 
3
 
 10
 
6
 
 cells/ml, respectively, for subsequent culture. The me-
dium employed in all tissue culture was serum-free HL-1 (Bio-
Whittaker) supplemented with 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME (Sigma
Chemical Co.), 4 mM of 
 
l
 
-glutamine, 100 U/ml of benzyl peni-
cillin, and 100 
 
m
 
g/ml of streptomycin sulfate (all three from
GIBCO BRL). All cultures were incubated at 37
 
8
 
C in a humidi-
fied atmosphere of 5% CO
 
2
 
.
 
Protein and Peptide Ags.
 
HEL was purchased from Sigma
Chemical Co. and then further purified on a Bio-Rex 70 column
(Bio-Rad Labs.). HEL p106–116 (NAWVAWRNRCK) was
purchased from Macromolecular Resources and found to be 95%
pure by mass spectrometry.
 
T Cell Proliferation Assay.
 
Splenocytes and LN cells were cul-
tured in 96-well plates at 6 
 
3 
 
10
 
5
 
 and 4 
 
3 
 
10
 
5
 
 cells/well, respec-
tively, in the presence or absence of Ag. Proliferation was mea-
sured by incorporation of 1 
 
m
 
Ci of [
 
3
 
H]thymidine (ICN, Inc.)
for the last 18 h of a 4-d culture. The cells were harvested onto
glass fiber filter mats (LKB-Wallac Ltd.) using a Mach III Har-
vester 96 (Tomtec), and [
 
3
 
H]thymidine incorporation was mea-
sured using a scintillation counter (Microbeta 
 
1
 
; LKB-Wallac).
 
ELISPOT Cellular Assays for Cytokine Production.
 
After 36 h
of culture in the presence or absence of Ag, splenocytes and LN 
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cells were washed once and adjusted to 5 
 
3 
 
10
 
6
 
 cells/ml in fresh,
supplemented HL-1 serum-free medium. IFN-
 
g
 
, IL-4, and IL-5
production was then determined using standard ELISPOT assays,
as described in detail elsewhere (21). In brief, cells were incu-
bated on nitrocellulose plates previously coated with anticytokine
mAb and blocked with 1% FBS/PBS for 24 h at multiple dilu-
tions. After washing and lysing of cells in chilled PBS/0.5%
Tween 20, bound cytokines were detected by adding biotiny-
lated anticytokine mAb directed to a nonoverlapping epitope on
the cytokine. After incubation of plates with streptavidin peroxi-
dase (Vector Labs.), plate-bound enzyme was visualized using
3-amino-9-ethyl carbazole (Sigma Chemical Co.) as a substrate.
Plates were washed in distilled water and dried before subsequent
visual spot enumeration under a dissecting microscope.
 
Assays for Serum Abs.
 
ELISA with anti–mouse Ig was used to
determine serum levels of Abs specific for HEL. Affinity-purified
rabbit Ab specific for IgG1 or IgG2a H chains were obtained
from Zymed Labs. In brief, Maxisorp Immunoplates were coated
for 1 h at 37
 
8
 
C with 50 
 
m
 
l per well of HEL diluted to 10 
 
m
 
g/ml
in carbonate/bicarbonate buffer, pH 9.6. After washing twice in
PBS/0.05% Tween 20, plates were blocked at 37
 
8
 
C for 1 h with
200 
 
m
 
l per well of a PBS/1% BSA solution. After two washes,
sera to be tested were then added at 50 
 
m
 
l per well in dilutions
ranging from 1/10 to 1/500 and incubated overnight at 4
 
8
 
C.
Pooled sera from HEL-immunized mice were used as a positive
standard. After three further washes in PBS/Tween 20, antiisotype
conjugate was added at an optimal (1/500) dilution in PBS/BSA and
incubated at 37
 
8
 
C for 1 h. After eight additional washes, the
amount of enzyme bound to the wells was assessed using 
 
p
 
-nitro-
phenyl phosphate as the substrate for 20–30 min at 37
 
8
 
C. The
plates were then assayed at OD 405 nm on a multiscan plate reader.
 
T Cell Receptor Repertoire Analysis.
 
Repertoire analyses were
performed using a modified protocol similar that described by
Pannetier et al. (22). Total RNA was isolated from cell suspensions
of individual samples using Trizol reagent according to product
instructions (GIBCO BRL Life Technologies). cDNA syntheses
were then performed using an oligo-dT primer (dT)
 
15
 
 according
to the manufacturer’s instructions (GIBCO BRL Life Technolo-
gies). From each cDNA, PCR reactions were then performed us-
ing a V
 
b
 
8.2 primer (CATTATTCATATGGTGCTGGC) and a
common C
 
b
 
 primer (CACTGATGTTCTGTGTGACA). Using
2 
 
m
 
l of this product as a template, run-off reactions were per-
formed with a single internal fluorescent primer for each J
 
b
 
tested, a 1-min 94
 
8
 
C denature and then five cycles of 94
 
8
 
C for
45 s, 60
 
8
 
C for 45 s, and 72
 
8
 
C for 45 s, followed by a 1-min exten-
sion at 72
 
8
 
C. These products were then denatured in formamide
and analyzed on an Applied Biosystems 310 Prism using Gene-
Scan 2.0 software (Perkin-Elmer Corp.). Labeled products were
analyzed separately or duplexed as four-color electrofluorographs.
These data determine peak areas and confirm appropriate product
specificity based upon size and color (primer specificity). The rel-
ative intensity of signal (RIS) value was calculated as the area un-
der the experimental peak divided by the area under the control
peak found within a Gaussian distribution. Peaks were normal-
ized before division. Control peaks obtained from either IFA/
CFA-immunized animals or naive animals gave equivalent RIS
values. RIS values 
 
.
 
4 are considered significant (22).
 
Results and Discussion
 
Neonatal Administration of HEL Inhibits the Clonal Expan-
sion of the Public Repertoire.
 
As all HEL-primed BALB/c
mice utilize an identical “public” clone that could be
readily followed, we measured its expansion in tolerized
and untolerized animals to determine whether the mecha-
nism of neonatal tolerance involves T cell deletion or an-
ergy. BALB/c mice were treated neonatally with HEL in
IFA (as described in Materials and Methods). Upon reach-
ing adulthood, spleens from neonatally treated animals that
had not been challenged in vivo were examined for T cell
response after in vitro stimulation with HEL. Fig. 1 shows
that adult BALB/c mice treated neonatally with HEL con-
tinue to mount a strong in vitro splenic proliferative re-
sponse to whole HEL as well as to its dominant determi-
nant, p106–116. Clearly, not all HEL-specific T cells are
deleted in this form of tolerance induction.
Because it was possible that these responses represented
an expansion of the public clone or a variety of other
clones of similar specificity, immunoscope analysis was
conducted on these samples. Fig. 2 A presents RIS values
(an expression of the relative expansion of the public clone;
see Materials and Methods) for the public clonotype. Nota-
bly, the data in the first column (from left) of Fig. 2 A illus-
trate that although the T cell response shown in Fig. 1 was
robust, it failed to show the characteristic V
 
b
 
8.2J
 
b
 
1.5 pub-
lic T cell expansion seen in the control HEL-immunized
animals (fifth column). Fig. 2 B illustrates representative
“immunoscope profiles” showing the different CDR3
chain lengths within the V
 
b
 
8.2J
 
b
 
1.5 repertoire. A Gaus-
Figure 1. Strong splenic proliferative responses persist after neonatal
administration of HEL. BALB/c mice received intraperitoneal injections
of 50 ml containing 50 mg of HEL emulsified in IFA within the first 18 h
of life and again at 72 h. Spleens were harvested at 8 wk of age, and the
splenic recall responses to HEL (h) or its dominant determinant, p106–
116 (e), were measured using a [3H]thymidine incorporation assay. Re-
sults are expressed as stimulation indices (S.I.; CPM in sample/CPM in
control). In vitro recall responses were significantly elevated (S.I. . 3) for
both HEL and p106–116. These data represent the average of three
groups of two to three mice. 
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adulthood with HEL, the Ig isotypes and cytokines pro-
duced in response to HEL were identified. When com-
pared with untolerized animals, the IgG2a anti-HEL re-
sponses (Th1) were significantly reduced in the neonatally
treated group. In fact, IgG2a responses were essentially un-
detectable in five out of seven animals in the tolerized
group and were marginal in the remaining two animals.
IgG1 responses (Th2), however, were not affected in six
out of seven tolerized animals (Fig. 3). In addition,
ELISPOT cytokine analysis revealed that IL-5 responses
were significantly increased in the neonatally treated ani-
mals, whereas IFN-
 
g
 
 responses were lower or remained
unchanged (data not shown).
 
Nasal Instillation Results in a Reduced Expansion of the
Dominant Clone.
 
In addition to neonatal tolerance, there
is now overwhelming evidence that peptide Ag provided
via nasal instillation has a pronounced effect on the animal’s
immune response to that particular determinant and in
some cases to other determinants on the same or different
molecules (23). The consequences of nasal administration
of Ag are not easily predictable from strain to strain; in
many instances, nasal instillation clearly results in a radical
Th1 to Th2 shift in the cytokine profile of the Ag-specific
T cells (24, 25). In other systems, there is a simple down-
regulation of T cell proliferation and cytokine secretion
Figure 2. Vb8.2Jb1.5 CDR3 length analysis of spleen cells re-
veals that neonatal administration of HEL inhibits the clonal ex-
pansion of the public repertoire. Groups of BALB/c mice were
treated neonatally with IFA–HEL (0.01, 100, or 500 mg) as de-
scribed in Materials and Methods. As shown in A, groups were
then challenged at 6 wk of age in the hind foot pads (z25 ml per
foot pad) with 100 mg of HEL emulsified 1:1 in CFA (Difco
Labs.). In A, each circle represents two to three animals whose cells were pooled for analysis (open circles represent individual animals, 0.01 mg group
only). An additional group that was treated with 100 mg of HEL–IFA as neonates was left unchallenged as adults. 14 d after challenge, spleens were har-
vested and cultured in vitro with HEL (10 mg/ml). Immunoscope analysis was conducted after 4 d of culture (see Materials and Methods). Results are dis-
played as RIS values of histogram peaks from Jb1.5 run-off reactions of Vb8.2 amplicons, corresponding to a CDR3 length of eight amino acids. The RIS
value plotted here equals the area of the experimental peak divided by the area of the naive control peak (shown in B). B shows representative histogram
comparisons of the Jb1.5 run-off reaction of the Vb8.2 amplicons. Normally, unimmunized animals display peaks in a Gaussian distribution centered on a
CDR3 length of nine. Only the low dose and IFA control groups, which were immunized with HEL–CFA at 6 wk of age, showed the highly significant
expansion (RIS . 4) of the HEL-specific public clone. B shows representative distributions of Vb8.2Jb1.5 for tolerized (normally distributed) and untol-
erized animals immunized with HEL–CFA. An inset is provided that shows an expanded view of the Gaussian distribution of the Vb8.2Jb1.5 products
from a tolerized individual. Note that when scaled to match, the signal detected from the expanded Vb8.2Jb1.5 products is largely reduced in comparison
with the tolerized (normally distributed) electrofluorograph. The peak that corresponds to an amino acid length of eight is indicated by the vertical arrow.
 
sian distribution is seen in the tolerized mouse (Fig. 2 B, in-
set) in which no clear expansion is measured. Fig. 2 B
shows the characteristic marked expansion of the public
clone with its CDR3 length of eight amino acids. Thus, al-
though many responsive clones can be measured that re-
spond to HEL and p106–116 (Fig. 1), there is no visible
expansion of the public clone in tolerized mice.
To determine whether the absence of the public expan-
sion to HEL or p106–116 could be attributed to immuni-
zation with an inappropriate adjuvant, animals neonatally
treated with HEL–IFA were immunized with HEL–CFA
as adults. As with neonatal treatment alone, these animals
responded with a strong splenic proliferative T cell re-
sponse; however, this response again lacked a significant
expansion of the dominant public clone (Fig. 2, second and
third columns). The absence of the expanded public clone
in the neonatally pretreated animals is strong evidence sup-
porting deletion or anergy as contributory mechanisms to
neonatal tolerance induction. Included in these data is a
third group of mice that were neonatally treated with an
extremely low dose (0.01 
 
m
 
g) of HEL–IFA. Notably, these
mice did not lack the characteristic expansion when subse-
quently challenged with HEL–CFA.
To further characterize the residual HEL-specific T cells
in mice that were both neonatally treated and challenged in 
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without a noticeable Th1 to Th2 shift (23). It is likely that
several factors, such as the peptide’s MHC binding affinity
as well as the array of TCR affinities for the peptide-bound
MHC complex, would influence the effect of nasal instilla-
tion on the Ag-specific immune response. Experiments in
our laboratory have shown that BALB/c mice nasally in-
stilled with HEL or its dominant determinant, p106–116,
mount a predominant Th2 T cell response upon subse-
quent in vivo challenge with HEL–CFA (25). Therefore,
to determine whether the residual HEL-specific T cell rep-
ertoire, remaining after neonatal treatment, was unique to
such pretreatment or indistinguishable from other toleriz-
ing regimes, we nasally instilled BALB/c mice with HEL
p106–116 and performed immunoscope analysis on splenic
T cells 14 d after subsequent HEL–CFA challenge. Similar
to the findings of a previous report (23), nasal instillation
resulted in a significant reduction of LN proliferative re-
sponses (Fig. 4 A). Splenic proliferative responses, how-
ever, were similar or higher between groups of animals na-
sally instilled with p106–116 (known to be Th2; reference
25; Fig. 4 B) and those nasally instilled with PBS alone
(Th1), indicating that cytokine deviation was not reflected
in the proliferative response. Interestingly, the most striking
difference seen in the nasally instilled group was revealed
by immunoscope analysis. As was the case in the neonatal
treatment experiments, BALB/c mice treated by nasal in-
stillation with p106–116 showed a dose-dependent de-
crease in the expansion of the HEL-specific public clone
(Fig. 5). Although not as dramatic as in the neonatally pre-
treated animals, there was a sixfold reduction seen in the
p106–116 group nasally instilled with 200 
 
m
 
g, which was
significant at the
 
 P 
 
, 
 
0.005 level (Fig. 5). In mice treated
similarly with HEL, a robust IL-5 response to p106–116
appears, whereas responses to subdominant and cryptic de-
terminants were unaffected (25).
Figure 3. Neonatally tolerized animals mount a predominant IgG1
anti-HEL response when challenged with Ag as adults. BALB/c mice
were neonatally tolerized with HEL emulsified in IFA or IFA alone, as de-
scribed in Fig. 2. As adults, they were challenged with HEL–CFA. Blood
samples were collected before organs were harvested, and the sera sepa-
rated from these samples were used in an ELISA to measure levels of anti-
HEL Ab isotypes. Only two of seven mice in the tolerized group
mounted an anti-HEL IgG2a (Th1-associated) response upon HEL in
vivo challenge, and then only marginally. In contrast, six of seven of the
mice showed strong IgG1 anti-HEL responses (associated with Th2 re-
sponses). Thus, when compared with untolerized control animals, neona-
tal tolerance resulted in a significant reduction in IgG2a (P , 0.005, Stu-
dent’s t test, indicated by *) and no significant change in IgG1 (P . 0.15).
Each circle represents the serum level of anti-HEL Abs of the indicated
isotype from a single animal. Results are expressed as OD. Immunoscope
analyses on T lymphocytes from pools of these animals are shown in Fig. 2.
Figure 4. Nasal administra-
tion of HEL p106–116 results in
a reduced LN but a significant
splenic proliferative response.
Animals were nasally instilled
twice with a total of 0 (s), 20
(e), or 200 mg (u) of HEL
p106–116 dissolved in 20 ml of
PBS; half of the dose was admin-
istered at each delivery, 7 d
apart. 10 d after the second in-
stillation, animals were immu-
nized in the hind foot pads with
100  mg of HEL emulsified in
CFA. 14 d thereafter, splenic
and LN restimulation cultures
were established, and responses
to HEL were measured in a
[3H]thymidine incorporation as-
say as described in Fig. 1. Re-
sults are presented as stimulation
indices. Pretreatment by nasal instillation resulted in a significant reduction of LN proliferative responses (A). However, as shown in B, splenic prolifer-
ative responses were similar or higher in groups of animals nasally instilled with p106–116 compared to those pretreated with PBS alone. Parallel spec-
tratype analyses of splenic lymphocytes from these nasally instilled animals are shown as RIS values in Fig. 5.700 T Cell Repertoires and Tolerance Induction
The Nature of the T Cell Repertoire Remaining after Neonatal
Tolerance. The data presented here indicate that clonal de-
letion or anergy can occur even though a significant T cell
response persists. The seemingly paradoxical result of a
quantitatively similar but qualitatively different response
suggests that in some situations, among T cells with similar
specificity, some can escape tolerance induction, whereas
others do not. These data can be explained by considering
the diversity of the HEL-specific T cell repertoire. Studies
of HEL-specific T cells in the BALB/c mouse have shown
that individual mice use from 2 to 20 different clones in re-
sponse to an HEL immunization (20). Each clone with a
unique TCR will exhibit an interaction with its ligand
along the continuum of affinities. The individuality of T
cell recognition is also evident in that T cells have unique
patterns of degeneracy (26, 27) and thereby cross-recognize
different ligands (our unpublished results). We may assume
that a given ligand can therefore signal for tolerance induc-
tion of only a subpopulation of Ag-specific T cells. Indeed,
we have observed that the Vb8.2Jb1.5, HEL-specific pub-
lic clone is more sensitive to tolerance induction than other
clones recognizing determinants within the p103–120 de-
terminant envelope. A simple explanation is that these T
cells bear T cell receptors with avidities that are sufficiently
sensitive to signals delivered by the HEL-pulsed APCs, re-
sulting in clonal silencing through elimination or anergy
induction. In addition, in these studies, many clones with
avidity similar to the public clone could have been affected
by the tolerance-inducing regimen without our knowl-
edge.
Furthermore, there is evidence that IL-2–producing Th1
cells are more susceptible to activation-induced cell death
than Th2 cells (28). In our study, there is a clear deficit of
at least one major TCR expansion in the tolerized animals
that are immunologically challenged. Therefore, we postu-
late that the Th2 nature of the residual splenic T cells arises
from the relatively weak interaction of their TCRs with
p106–116-bound MHC class II complexes. This notion is
supported by the finding that low concentrations of Ag
tend to promote the development of Th2 cells (17, 18, 29).
Therefore, a low-affinity TCR might signal for a similar
response. In accord with this concept, it has been shown in
the I-Au system that Th2 responses to the NH2-terminal
region of myelin basic protein result from sparse ligand dis-
play, low-affinity TCR, or both. However, T cells with a
higher avidity receptor may adopt either a Th1 or Th2
phenotype depending on the density of the ligand (16). In
short, in the spectrum of p103–120-specific T cells, there
exist some low-avidity T cells that are stimulated by HEL-
derived peptides from this region to respond in a Th2 fash-
ion just as there exist altered peptide ligands capable of in-
ducing Th2 responses (30).
Determinant Display and the Induction of Tolerance. It has
been shown that tolerance is induced best to well-pro-
cessed and -presented determinants and that subdominant
and cryptic determinants are less efficient at tolerance in-
duction using whole protein Ags (31, 32). Conceivably,
the recall response to HEL seen in Fig. 1 might be aug-
mented by responses to previously subdominant and latent
cryptic determinants. This could explain why the response
to p106–116 is slightly lower than that to HEL (Fig. 1). In
addition, it has been postulated that the same peptide can
bind in multiple overlapping registers (our unpublished re-
sults) or possibly in multiple conformations to the class II
MHC molecule (33). Thus, a portion of the residual re-
sponse measured after tolerance induction might be specific
for a particular conformation or register that is disfavored
when processed from the intact protein. In either case, the
Th2 phenotype can be explained in terms of a low density
of determinant display in the appropriate conformation/
register, which, as in the case of a low Ag concentration,
would favor the development of Th2 cells (17, 18). Perhaps
several of these possibilities simultaneously contribute to
our observed results.
A third consideration, which is not addressed experi-
mentally at present, is the cytokine milieu surrounding the
differentiating T cell. The amount of IL-12 and IL-4 in this
milieu has been shown to have profound effects on the de-
velopment of Th1 and Th2 cells, respectively (34). We
cannot dismiss the importance of these effects. In our ex-
periments, however, both tolerized and control animals
were immunized with HEL emulsified in CFA. Because of
this, the cytokine milieu should have remained largely con-
stant between tolerized and untolerized groups, except for
cytokines produced by HEL-specific cells, which could
have helped to drive the response one way or the other. In
fact, adult immunization with HEL–IFA, presumably a
Th2-inducing stimulus (3), does expand the public clone
(data not shown). Thus, the probability of a T cell respond-
ing to an antigenic stimulus in a Th1 or Th2 fashion de-
pends on multiple factors, one of which is the particular
TCR borne by the T cell.
Tolerance Redefined. In earlier experiments when Ab-
producing B cell activity was sought after neonatal or adult
tolerance to high-level Ag (BSA), none was found (35).
Furthermore, early T cell tolerance experiments were in-
Figure 5. Nasal instillation of
p106–116 results in a significant
reduction of the Vb8.2Jb1.5
public expansion. BALB/c mice
were nasally instilled twice with
0, 10, or 100 mg of HEL p106–
116 as described in Fig. 4. TCR
spectratype analysis was con-
ducted after 4 d of in vitro cul-
ture with Ag (10 mg/ml). Re-
sults are displayed as RIS values
as described in Materials and
Methods. Each circle represents
two animals whose cells were
pooled for analysis. As was the
case in the neonatally pretreated
animals, animals nasally instilled
with p106–116 showed a marked
decrease in the expansion of the
HEL-specific public clone. In comparison to the control group, mice na-
sally instilled with 200 mg did not exhibit a significantly expanded public
repertoire (P , 0.005, Student’s t test).701 Maverakis et al.
terpreted to indicate that central T cell activity had been
inhibited. Therefore, in light of the finding that consider-
able residual responsiveness remains or is revealed in the
spleen when the appropriate T cell population is studied
directly despite neonatal or nasal “tolerance regimens,” the
term “tolerance” needs to be carefully defined. Classic ex-
periments by Billingham et al. (2) and Owen et al. (36)
showed that fetal or neonatal exposure to transplant Ags re-
sulted in an immune system that would tolerate and not re-
act against these same alloantigens. Although it is possible
that all alloreactive cells were simply converted to a nonag-
gressive phenotype (Th2), it is likely that as shown here
with HEL, many of the highly reactive cells could have
been deleted or anergized. Accordingly, the residual T cell
repertoire directed to any self-Ag would largely remain as a
contingent of cells capable of responding to many of its
subdominant/cryptic determinants, regardless of the extent
of previous tolerogenic exposure. Within the body of T
cells directed against the dominant determinant(s), the
high-avidity members would become tolerized, whereas
the lower avidity group should remain available to respond
to sufficient levels of appropriate versions of the dominant
determinant. It appears that complete silencing of the
whole contingent of immune cells directed against the
whole Ag cannot be achieved. Nevertheless, the term “tol-
erance,” implying a qualitative variety of ways of safely
dealing with self-Ags, might usefully be retained as an en-
velope term, providing that the context of its usage does
not overstep its limitations.
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